6-K ·Filed Jul 1, 2026

RDY

DR REDDYS LABORATORIES LTD
NEUTRAL
Impact 2/10
Horizondays Processed3mo ago SEC0001575872-26-000475
Notable filing: 6-K
Actionable Insight • Neutral

This is a routine filing with no material new information. Traders should monitor upcoming earnings or press releases for any operational or financial updates.

DirectionNeutral
Confidencelow
Horizondays
Latest settled — T+20d ⚠ clustered
RDY ▼ -15.94% at T+20d
NEUTRAL call ✗ call lost -15.94% · α vs SPY -13.75% · entry $13.99 → $11.76
Next anchor: T+60d due 7d ago
Latest observation: T+57 -10.53% FF3 residual α
Entry anchored
Jun 30, 03:59 PM ET
via exchange tick
T+1d
+2.79%
call +2.79% · α +2.92%
$14.38
settled 3mo ago
T+5d
+4.57%
call +4.57% · α +4.31%
$14.63
settled 3mo ago
T+20d
-15.94%
call -15.94% · α -13.75%
$11.76
settled 2mo ago
T+60d
—
call — · α —
—
due 7d ago

Price Chart

Loading chart...

Executive Summary

Dr. Reddy's Laboratories filed a Form 6-K on July 1, 2026, to furnish an intimation (Exhibit 99.1) to the SEC. The filing is a routine foreign issuer report with no material financial disclosures, business updates, or operational changes. The attached document content is not available for review, so the analysis is based solely on the filing metadata.

Key Facts

  • Form 6-K filed July 1, 2026, as a routine foreign private issuer report
  • Exhibit 99.1 is an intimation dated July 1, 2026 — content of this exhibit is unavailable
  • No financial results, guidance, material agreements, or operational updates disclosed in the filing
  • Company has 834,656,970 equity shares outstanding per recent 20-F filing (May 29, 2026)
  • Analysis based on filing metadata only — document content was unavailable

Financial Impact

No financial figures disclosed in this filing

Risk Factors

  • Lack of document content limits visibility into the substance of the intimation filed as Exhibit 99.1
  • No forward-looking guidance or strategic commentary provided in the filing

Market Snapshot

Exchange
NYSE
Sector
Pharmaceutical Preparations
Analyst Consensus
52% bullish (44 analysts)

Investment Themes

Biotech & Drug Discovery

Documents Analyzed

This report is based on 3 SEC documents filed with EDGAR.

DocumentAccession Number
6-K Filing (Primary)0001575872-26-000475
Document: 0001575872-26-000475-index.html0001575872-26-000475
Document: 0001575872-26-000475.txt0001575872-26-000475
51 reports for RDY
Performance horizon
67% Hit rate 6 of 9 directional calls best @ T+20▲ +23.28%Jun 26, 2026
Filters
Rows
Reports for RDY — sortable, filterable
TypeNow
Sep 14, 2026
18d ago
6-K
NEUTRAL ★ 3/10
$11.91 $11.55▼ −3.02%▼ −2.56%$12.25 (+2.85%)
Sep 10, 2026
22d ago
6-K
NEUTRAL ★ 5/10
$11.71 $11.90▲ +1.62%▲ +0.77%$12.25 (+4.61%)
Sep 10, 2026
22d ago
6-K
NEUTRAL ★ 2/10
$11.71 $11.90▲ +1.62%▲ +0.77%$12.25 (+4.61%)
Aug 26, 2026
5w ago
6-K
NEUTRAL ★ 2/10
$12.22 $12.16▼ −0.49%▼ −1.15%$12.25 (+0.25%)
Aug 17, 2026
6w ago
6-K
MIXED ★ 5/10
$12.11 $12.15▲ +0.33%▲ +1.01%$12.25 (+1.16%)
Aug 13, 2026
7w ago
6-K
NEUTRAL ★ 3/10
$12.42 $12.27▼ −1.21%▼ −1.01%$12.25 (−1.37%)
Aug 10, 2026
7w ago
6-K
NEUTRAL ★ 2/10
$12.15 $12.45▲ +2.47%▲ +2.79%$12.25 (+0.82%)
Aug 3, 2026
8w ago
6-K
BULLISH ★ 6/10
$12.07 $12.10▲ +0.25%▼ −1.55%$12.25 (+1.49%)
Jul 29, 2026
9w ago
6-K
NEUTRAL ★ 4/10
$11.76 $11.83▲ +0.60%▼ −1.08%$12.25 (+4.17%)
Jul 23, 2026
10w ago
6-K
NEUTRAL ★ 2/10
$11.80 $11.79▼ −0.08%▼ −0.19%$12.25 (+3.81%)
Showing 10 of 51

US Market Status

Market Closed — Opens Mon (65h 27m)

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access